You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZimelidine
Accession NumberDB04832
TypeSmall Molecule
GroupsWithdrawn
DescriptionZimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. After its ban, it was succeeded by fluvoxamine and fluoxetine (derived from the antihistamine diphenhydramine) in that order, and the other SSRIs.
Structure
Thumb
Synonyms
(Z)-3-(4'-Bromophenyl)-3-(3''-pyridyl)dimethylallylamine
(Z)-3-[1-(p-Bromophenyl)-3-(dimethylamino)propenyl]pyridine
(z)-zimelidine
Cis-zimelidine
Zimeldine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII3J928617DW
CAS number56775-88-3
WeightAverage: 317.224
Monoisotopic: 316.057511201
Chemical FormulaC16H17BrN2
InChI KeyInChIKey=OYPPVKRFBIWMSX-SXGWCWSVSA-N
InChI
InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-
IUPAC Name
[3-(4-bromophenyl)-3-(pyridin-3-yl)prop-2-en-1-yl]dimethylamine
SMILES
CN(C)CC=C(C1=CC=C(Br)C=C1)C1=CN=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropenes. These are compounds containing a phenylpropene moiety, which consists of a propene substituent bound to a phenyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropenes
Direct ParentPhenylpropenes
Alternative Parents
Substituents
  • Phenylpropene
  • Styrene
  • Halobenzene
  • Bromobenzene
  • Pyridine
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsZimelidine was the first marketed selective serotonin reuptake inhibitor (SSRI) antidepressant. It is a pyridylallylamine, structurally different from other antidepressants.
Mechanism of actionThe antidepressant actions of zimelidine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Zimelidine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.972
Blood Brain Barrier+0.9382
Caco-2 permeable+0.7284
P-glycoprotein substrateSubstrate0.6049
P-glycoprotein inhibitor INon-inhibitor0.8435
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.5919
CYP450 2C9 substrateNon-substrate0.8893
CYP450 2D6 substrateNon-substrate0.6656
CYP450 3A4 substrateSubstrate0.5541
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8185
Ames testNon AMES toxic0.8077
CarcinogenicityNon-carcinogens0.807
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.5787 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8348
hERG inhibition (predictor II)Inhibitor0.6614
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0239 mg/mLALOGPS
logP3.39ALOGPS
logP3.51ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)8.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.94 m3·mol-1ChemAxon
Polarizability30.96 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Caille G, Kouassi E, de Montigny C: Pharmacokinetic study of zimelidine using a new GLC method. Clin Pharmacokinet. 1983 Nov-Dec;8(6):530-40. [PubMed:6228368 ]
  2. Godbout R, Montplaisir J: The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol. 1986;9(1):46-51. [PubMed:2950994 ]
External Links
ATC CodesN06AB02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Zimelidine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Zimelidine.
AcarboseZimelidine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Zimelidine.
AcenocoumarolZimelidine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Zimelidine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zimelidine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Zimelidine.
Acetylsalicylic acidZimelidine may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Zimelidine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Zimelidine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zimelidine.
AlbiglutideZimelidine may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Zimelidine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Zimelidine.
AlfentanilAlfentanil may increase the serotonergic activities of Zimelidine.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Zimelidine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Zimelidine.
AlogliptinZimelidine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Zimelidine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zimelidine.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Zimelidine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Zimelidine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zimelidine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zimelidine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Zimelidine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zimelidine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Zimelidine.
AmoxapineZimelidine may increase the serotonergic activities of Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Zimelidine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Zimelidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zimelidine.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Zimelidine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Zimelidine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Zimelidine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Zimelidine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Zimelidine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Zimelidine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Zimelidine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Zimelidine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zimelidine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Zimelidine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Zimelidine.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Zimelidine.
BendroflumethiazideZimelidine may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Zimelidine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Zimelidine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Zimelidine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Zimelidine.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Zimelidine.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Zimelidine.
BezitramideBezitramide may increase the serotonergic activities of Zimelidine.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Zimelidine.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Zimelidine.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Zimelidine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Zimelidine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Zimelidine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Zimelidine.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Zimelidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zimelidine.
BromocriptineZimelidine may increase the hypoglycemic activities of Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Zimelidine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Zimelidine.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Zimelidine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zimelidine.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Zimelidine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Zimelidine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zimelidine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zimelidine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Zimelidine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Zimelidine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Zimelidine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Zimelidine.
ButorphanolButorphanol may increase the serotonergic activities of Zimelidine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Zimelidine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Zimelidine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Zimelidine.
CanagliflozinZimelidine may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zimelidine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Zimelidine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zimelidine.
CarfentanilCarfentanil may increase the serotonergic activities of Zimelidine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Zimelidine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zimelidine.
CaroxazoneCaroxazone may increase the serotonergic activities of Zimelidine.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Zimelidine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Zimelidine.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Zimelidine.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Zimelidine.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Zimelidine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Zimelidine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zimelidine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zimelidine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Zimelidine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zimelidine.
ChlorothiazideZimelidine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zimelidine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zimelidine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Zimelidine.
ChlorpropamideZimelidine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zimelidine.
ChlorthalidoneZimelidine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zimelidine.
CimetidineThe metabolism of Zimelidine can be decreased when combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Zimelidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zimelidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Zimelidine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Zimelidine.
CitalopramCitalopram may increase the serotonergic activities of Zimelidine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Zimelidine.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Zimelidine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Zimelidine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Zimelidine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Zimelidine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Zimelidine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Zimelidine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Zimelidine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Zimelidine.
ClomipramineZimelidine may increase the serotonergic activities of Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Zimelidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Zimelidine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Zimelidine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Zimelidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zimelidine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Zimelidine.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Zimelidine.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Zimelidine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Zimelidine.
CodeineCodeine may increase the serotonergic activities of Zimelidine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Zimelidine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Zimelidine.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Zimelidine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Zimelidine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zimelidine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Zimelidine.
CyproheptadineThe therapeutic efficacy of Zimelidine can be decreased when used in combination with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Zimelidine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Zimelidine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Zimelidine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Zimelidine.
DapagliflozinZimelidine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zimelidine.
DapoxetineZimelidine may increase the serotonergic activities of Dapoxetine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Zimelidine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Zimelidine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Zimelidine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Zimelidine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Zimelidine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Zimelidine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Zimelidine.
DesmopressinThe risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Zimelidine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Zimelidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zimelidine.
DextromethorphanZimelidine may increase the serotonergic activities of Dextromethorphan.
DextromoramideDextromoramide may increase the serotonergic activities of Zimelidine.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Zimelidine.
DezocineDezocine may increase the serotonergic activities of Zimelidine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zimelidine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Zimelidine.
DicoumarolZimelidine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Zimelidine.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Zimelidine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Zimelidine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Zimelidine.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Zimelidine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Zimelidine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Zimelidine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Zimelidine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Zimelidine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Zimelidine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zimelidine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Zimelidine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Zimelidine.
DisopyramideZimelidine may increase the hypoglycemic activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Zimelidine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Zimelidine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Zimelidine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Zimelidine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Zimelidine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Zimelidine.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Zimelidine.
DPDPEDPDPE may increase the serotonergic activities of Zimelidine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Zimelidine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Zimelidine.
DulaglutideZimelidine may increase the hypoglycemic activities of Dulaglutide.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Zimelidine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Zimelidine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Zimelidine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Zimelidine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Zimelidine.
EmpagliflozinZimelidine may increase the hypoglycemic activities of Empagliflozin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Zimelidine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Zimelidine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Zimelidine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Zimelidine.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Zimelidine.
EscitalopramEscitalopram may increase the serotonergic activities of Zimelidine.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Zimelidine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Zimelidine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Zimelidine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Zimelidine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Zimelidine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zimelidine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Zimelidine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zimelidine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Zimelidine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zimelidine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zimelidine.
Ethyl biscoumacetateZimelidine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zimelidine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zimelidine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Zimelidine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Zimelidine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Zimelidine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Zimelidine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Zimelidine.
EtoperidoneZimelidine may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Zimelidine.
EtorphineEtorphine may increase the serotonergic activities of Zimelidine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Zimelidine.
ExenatideZimelidine may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Zimelidine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Zimelidine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Zimelidine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zimelidine.
FenfluramineFenfluramine may increase the serotonergic activities of Zimelidine.
FentanylFentanyl may increase the serotonergic activities of Zimelidine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Zimelidine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Zimelidine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Zimelidine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Zimelidine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Zimelidine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zimelidine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Zimelidine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zimelidine.
FluoxetineFluoxetine may increase the serotonergic activities of Zimelidine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zimelidine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zimelidine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zimelidine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zimelidine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Zimelidine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Zimelidine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Zimelidine.
FluvoxamineZimelidine may increase the serotonergic activities of Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Zimelidine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Zimelidine.
FurazolidoneFurazolidone may increase the serotonergic activities of Zimelidine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zimelidine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Zimelidine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Zimelidine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Zimelidine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Zimelidine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Zimelidine.
GliclazideZimelidine may increase the hypoglycemic activities of Gliclazide.
GlimepirideZimelidine may increase the hypoglycemic activities of Glimepiride.
GlipizideZimelidine may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Zimelidine.
GlyburideZimelidine may increase the hypoglycemic activities of Glyburide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Zimelidine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Zimelidine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Zimelidine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Zimelidine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zimelidine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Zimelidine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Zimelidine.
HeroinHeroin may increase the serotonergic activities of Zimelidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zimelidine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Zimelidine.
HydrochlorothiazideZimelidine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Zimelidine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Zimelidine.
HydroflumethiazideZimelidine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Zimelidine.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Zimelidine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Zimelidine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Zimelidine.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Zimelidine.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Zimelidine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Zimelidine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Zimelidine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Zimelidine.
IndalpineZimelidine may increase the serotonergic activities of Indalpine.
IndapamideZimelidine may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Zimelidine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Zimelidine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Zimelidine.
Insulin AspartZimelidine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirZimelidine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineZimelidine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineZimelidine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanZimelidine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproZimelidine may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Zimelidine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Zimelidine.
IproniazidIproniazid may increase the serotonergic activities of Zimelidine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Zimelidine.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Zimelidine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Zimelidine.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Zimelidine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zimelidine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zimelidine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Zimelidine.
KetobemidoneKetobemidone may increase the serotonergic activities of Zimelidine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Zimelidine.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Zimelidine.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Zimelidine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Zimelidine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zimelidine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Zimelidine.
LanreotideZimelidine may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Zimelidine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Zimelidine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Zimelidine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Zimelidine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Zimelidine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Zimelidine.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Zimelidine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Zimelidine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Zimelidine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Zimelidine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Zimelidine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Zimelidine.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Zimelidine.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Zimelidine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Zimelidine.
LevorphanolLevorphanol may increase the serotonergic activities of Zimelidine.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Zimelidine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zimelidine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Zimelidine.
LinezolidLinezolid may increase the serotonergic activities of Zimelidine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Zimelidine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Zimelidine.
LiraglutideZimelidine may increase the hypoglycemic activities of Liraglutide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Zimelidine.
LofentanilLofentanil may increase the serotonergic activities of Zimelidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Zimelidine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Zimelidine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zimelidine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Zimelidine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zimelidine.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Zimelidine.
Lu AA21004Zimelidine may increase the serotonergic activities of Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zimelidine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Zimelidine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Zimelidine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zimelidine.
MebanazineMebanazine may increase the serotonergic activities of Zimelidine.
MecaserminZimelidine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Zimelidine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Zimelidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Zimelidine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Zimelidine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zimelidine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zimelidine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zimelidine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zimelidine.
MetforminZimelidine may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Zimelidine.
MethadoneMethadone may increase the serotonergic activities of Zimelidine.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Zimelidine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zimelidine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Zimelidine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zimelidine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Zimelidine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Zimelidine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zimelidine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zimelidine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zimelidine.
MethyclothiazideZimelidine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueZimelidine may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zimelidine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Zimelidine.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Zimelidine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zimelidine.
MetolazoneZimelidine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Zimelidine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Zimelidine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Zimelidine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zimelidine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Zimelidine.
MifepristoneZimelidine may increase the hypoglycemic activities of Mifepristone.
MiglitolZimelidine may increase the hypoglycemic activities of Miglitol.
MilnacipranZimelidine may increase the serotonergic activities of Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Zimelidine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Zimelidine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zimelidine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Zimelidine.
MoclobemideMoclobemide may increase the serotonergic activities of Zimelidine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Zimelidine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Zimelidine.
MorphineMorphine may increase the serotonergic activities of Zimelidine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Zimelidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Zimelidine.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Zimelidine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Zimelidine.
NalbuphineNalbuphine may increase the serotonergic activities of Zimelidine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Zimelidine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Zimelidine.
NateglinideZimelidine may increase the hypoglycemic activities of Nateglinide.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Zimelidine.
NialamideNialamide may increase the serotonergic activities of Zimelidine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Zimelidine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Zimelidine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Zimelidine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Zimelidine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zimelidine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Zimelidine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Zimelidine.
NormethadoneNormethadone may increase the serotonergic activities of Zimelidine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zimelidine.
OctamoxinOctamoxin may increase the serotonergic activities of Zimelidine.
OctreotideZimelidine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zimelidine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Zimelidine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zimelidine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Zimelidine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zimelidine.
OpiumOpium may increase the serotonergic activities of Zimelidine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zimelidine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Zimelidine.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Zimelidine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zimelidine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zimelidine.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Zimelidine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zimelidine.
OxycodoneOxycodone may increase the serotonergic activities of Zimelidine.
OxymorphoneOxymorphone may increase the serotonergic activities of Zimelidine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Zimelidine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zimelidine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Zimelidine.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Zimelidine.
PargylinePargyline may increase the serotonergic activities of Zimelidine.
ParoxetineParoxetine may increase the serotonergic activities of Zimelidine.
PasireotideZimelidine may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Zimelidine.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Zimelidine.
PentamidineZimelidine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Zimelidine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zimelidine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Zimelidine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Zimelidine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zimelidine.
PethidinePethidine may increase the serotonergic activities of Zimelidine.
PhenelzinePhenelzine may increase the serotonergic activities of Zimelidine.
PhenindioneZimelidine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Zimelidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Zimelidine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Zimelidine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Zimelidine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Zimelidine.
PhenprocoumonZimelidine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Zimelidine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Zimelidine.
PimozideThe risk or severity of adverse effects can be increased when Zimelidine is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Zimelidine.
PioglitazoneZimelidine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Zimelidine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Zimelidine.
PirlindolePirlindole may increase the serotonergic activities of Zimelidine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Zimelidine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Zimelidine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Zimelidine.
PolythiazideZimelidine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Zimelidine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Zimelidine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Zimelidine.
PractololThe serum concentration of Practolol can be increased when it is combined with Zimelidine.
PramlintideZimelidine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Zimelidine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Zimelidine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Zimelidine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Zimelidine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Zimelidine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Zimelidine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zimelidine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Zimelidine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Zimelidine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Zimelidine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zimelidine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Zimelidine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Zimelidine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Zimelidine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zimelidine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Zimelidine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Zimelidine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Zimelidine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zimelidine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Zimelidine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Zimelidine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zimelidine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zimelidine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Zimelidine.
QuinethazoneZimelidine may increase the hyponatremic activities of Quinethazone.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Zimelidine.
QuinineZimelidine may increase the hypoglycemic activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Zimelidine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Zimelidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Zimelidine.
RasagilineRasagiline may increase the serotonergic activities of Zimelidine.
RemifentanilRemifentanil may increase the serotonergic activities of Zimelidine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zimelidine.
RepaglinideZimelidine may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zimelidine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Zimelidine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Zimelidine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Zimelidine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Zimelidine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Zimelidine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Zimelidine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Zimelidine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Zimelidine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Zimelidine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zimelidine.
RosiglitazoneZimelidine may increase the hypoglycemic activities of Rosiglitazone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zimelidine.
SafrazineSafrazine may increase the serotonergic activities of Zimelidine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Zimelidine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Zimelidine.
SaxagliptinZimelidine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zimelidine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zimelidine.
SelegilineSelegiline may increase the serotonergic activities of Zimelidine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Zimelidine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Zimelidine.
SertralineSertraline may increase the serotonergic activities of Zimelidine.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zimelidine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Zimelidine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Zimelidine.
SitagliptinZimelidine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Zimelidine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Zimelidine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Zimelidine.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Zimelidine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Zimelidine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Zimelidine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Zimelidine.
SufentanilSufentanil may increase the serotonergic activities of Zimelidine.
SulfadiazineZimelidine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleZimelidine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleZimelidine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zimelidine.
SunitinibZimelidine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Zimelidine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Zimelidine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Zimelidine.
TapentadolTapentadol may increase the serotonergic activities of Zimelidine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Zimelidine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Zimelidine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Zimelidine.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Zimelidine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zimelidine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Zimelidine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zimelidine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Zimelidine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zimelidine.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zimelidine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zimelidine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Zimelidine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Zimelidine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zimelidine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zimelidine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Zimelidine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Zimelidine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Zimelidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Zimelidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Zimelidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zimelidine.
TolazamideZimelidine may increase the hypoglycemic activities of Tolazamide.
TolbutamideZimelidine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zimelidine.
ToloxatoneToloxatone may increase the serotonergic activities of Zimelidine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Zimelidine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Zimelidine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Zimelidine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Zimelidine.
TramadolZimelidine may increase the neuroexcitatory activities of Tramadol.
TramadolTramadol may increase the serotonergic activities of Zimelidine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Zimelidine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Zimelidine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Zimelidine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Zimelidine.
TrazodoneZimelidine may increase the serotonergic activities of Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zimelidine.
TrichlormethiazideZimelidine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zimelidine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zimelidine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zimelidine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Zimelidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Zimelidine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Zimelidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Zimelidine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Zimelidine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Zimelidine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Zimelidine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Zimelidine.
VilazodoneZimelidine may increase the serotonergic activities of Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Zimelidine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Zimelidine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Zimelidine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zimelidine.
VortioxetineZimelidine may increase the serotonergic activities of Vortioxetine.
WarfarinZimelidine may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Zimelidine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zimelidine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Zimelidine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Zimelidine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Zimelidine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zimelidine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Zimelidine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Zimelidine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Zimelidine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zimelidine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Egashira T, Takayama F, Yamanaka Y: The inhibition of monoamine oxidase activity by various antidepressants: differences found in various mammalian species. Jpn J Pharmacol. 1999 Sep;81(1):115-21. [PubMed:10580379 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Egashira T, Takayama F, Yamanaka Y: Effects of long-term treatment with dicyclic, tricyclic, tetracyclic, and noncyclic antidepressant drugs on monoamine oxidase activity in mouse brain. Gen Pharmacol. 1996 Jul;27(5):773-8. [PubMed:8842678 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 15:01 / Updated on August 17, 2016 12:24